J
J. C. Biggs
Researcher at St. Vincent's Health System
Publications - 72
Citations - 1755
J. C. Biggs is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Transplantation & Bone marrow. The author has an hindex of 25, co-authored 72 publications receiving 1731 citations.
Papers
More filters
Journal ArticleDOI
A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis.
John Moore,Peter Brooks,Sam Milliken,J. C. Biggs,David D.F. Ma,Malcolm L. Handel,Paul Cannell,Rob Will,Simon Rule,David Joske,Bob Langlands,Kerry Taylor,Joe O'Callaghan,Jeff Szer,Ian P. Wicks,Geoff McColl,Frances Passeullo,John A. Snowden +17 more
TL;DR: Hemopoietic stem cell transplantation can be performed safely in patients with RA, and initial results indicate significant responses in patientsWith severe, treatment-resistant disease.
Journal ArticleDOI
Tranexamic acid and upper gastrointestinal haemorrhage--a double-blind trial.
TL;DR: There appeared to be a reduction in the transfusion rate after the first three days of hospitalization in the treatment group, and there were no significant differences in mortality or in side-effects between the two groups.
Journal ArticleDOI
A Randomised, Blinded, Placebo-Controlled, Dose Escalation Study of the Tolerability and Efficacy of Filgrastim for Haemopoietic Stem Cell Mobilisation in Patients With Severe Active Rheumatoid Arthritis
John A. Snowden,J. C. Biggs,Sam Milliken,A. Fuller,D. Staniforth,F. Passuello,J. Renwick,Peter Brooks +7 more
TL;DR: It is concluded that filgrastim may be administered to patients with severe active RA for effective stem cell mobilisation and 10 μg/kg/day remains the dose of choice in view of more efficient CD34+ cell mobilisations.
Journal ArticleDOI
Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2.
J. C. Biggs,Jeff Szer,P. Crilley,Kerry Atkinson,K. Downs,Anthony J. Dodds,Alan J. Concannon,B. Avalos,P. Tutschka,N. Kapoor,Isadore Brodsky,David Topolsky,S Bulova,Edward A. Copelan +13 more
TL;DR: It is indicated that BuCy2 is a useful conditioning regimen for marrow transplantation in patients with CML and results in similar survival statistics and transplant-related mortality as would be expected with conditioning regimens containing total body irradiation.
Journal ArticleDOI
The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation.
TL;DR: The toxicity of the conditioning regimen of high dose busulphan (Bu and Cy) and cyclophosphamide (Cy) has been compared to fractionated total body irradiation (TBI) 12‐14 Gy.